SLC52A2 Antibody

What is SLC52A2 and what is its significance in human physiology?

SLC52A2 encodes a membrane protein belonging to the riboflavin transporter protein family (RFVT2) that mediates the transport of riboflavin (vitamin B2) across cell membranes . This function is crucial since humans cannot synthesize riboflavin and must obtain it through intestinal absorption . The biologically active forms of riboflavin, FMN and FAD, are essential cofactors for numerous metabolic processes involving carbohydrates, amino acids, and lipids .

The canonical human SLC52A2 protein consists of 445 amino acid residues with a molecular mass of approximately 45.8 kDa . It is predominantly localized in the cell membrane and is highly expressed in the brain, fetal brain, and salivary gland . The protein's structure includes 11 α-helices that cross the membrane and two large hydrophilic loops, with one loop containing several negatively charged amino acids clustered in its center .

Mutations in the SLC52A2 gene have been linked to Brown-Vialetto-Van Laere syndrome, a rare neurological disorder characterized by infancy onset . Additionally, riboflavin deficiency has been identified as a risk factor for cancer, cardiovascular disease, and neurodegeneration .

What types of SLC52A2 antibodies are available for research applications?

Several types of SLC52A2 antibodies are available for research purposes, each with specific applications and characteristics:

Polyclonal antibodies against SLC52A2, such as the Rabbit Anti-Human SLC52A2 Polyclonal Antibody, are commonly used for Western blot, immunofluorescence, and ELISA applications . These antibodies recognize multiple epitopes on the SLC52A2 protein, providing strong signal amplification but potentially more background compared to monoclonal alternatives.

When selecting an anti-SLC52A2 antibody, researchers should consider the specific application (WB, IF, IHC, ELISA), the species reactivity needed, and the particular domain or epitope of interest on the SLC52A2 protein.

How is SLC52A2 expression distributed across normal and pathological tissues?

SLC52A2 shows a distinctive expression pattern across human tissues with significant implications for both physiological function and pathological conditions:

In normal tissues, SLC52A2 is highly expressed in the brain, fetal brain, and salivary gland . Analysis using the "gganatogram" and "ggpubr" R software packages has revealed SLC52A2 expression patterns across 31 normal human tissues, with some tissue-specific and gender-specific variations .

In pathological contexts, SLC52A2 demonstrates significantly altered expression patterns. Bioinformatic analyses using TCGA and GEO databases show that SLC52A2 is highly expressed in almost all examined tumor types compared to corresponding normal tissues . Specifically, significant upregulation has been confirmed in multiple cancers including:

• Bladder cancer (BLCA)

• Breast cancer (BRCA)

• Cholangiocarcinoma (CHOL)

• Colorectal cancers (COAD, READ)

• Esophageal cancer (ESCA)

• Glioblastoma (GBM)

• Head and neck squamous cell carcinoma (HNSC)

• Kidney cancers (KICH, KIRC, KIRP)

• Liver cancer (LIHC)

• Lung cancers (LUAD, LUSC)

• Prostate cancer (PRAD)

• Stomach adenocarcinoma (STAD)

• Thyroid cancer (THCA)

• Uterine corpus endometrial carcinoma (UCEC)

Interestingly, SLC52A2 expression correlates with clinical features across several cancer types. Higher expression levels are associated with advanced tumor grades (3-4) in cervical, kidney, brain, liver, and endometrial cancers, and with advanced clinical stages (III-IV) in adrenocortical, breast, colorectal, head and neck, kidney, and thymic cancers .

How can researchers validate the specificity of SLC52A2 antibodies for experimental applications?

Validating antibody specificity is critical for ensuring reliable experimental results. For SLC52A2 antibodies, researchers should implement a multi-step validation process:

• Western Blot Validation: The SLC52A2 protein has a predicted molecular weight of 45.8 kDa . A specific antibody should detect a primary band at this size. The specificity can be confirmed using:

  • Positive controls: Tissues with known high expression (brain, salivary gland)

  • Negative controls: Tissues with low/no expression or SLC52A2 knockout cells

  • Peptide competition assays: Pre-incubating the antibody with the immunizing peptide should eliminate specific binding

• Immunohistochemical/Immunofluorescence Validation:

  • Correlate staining patterns with known expression data from RNA-seq databases

  • Compare staining patterns using multiple antibodies targeting different epitopes

  • Include isotype controls to assess non-specific binding

  • Use SLC52A2 knockdown/knockout samples as negative controls

• Recombinant Protein Expression:

  • Express recombinant SLC52A2 with epitope tags in heterologous systems

  • Confirm co-localization of anti-SLC52A2 antibody signal with epitope tag antibodies

• Genetic Validation:

  • siRNA or CRISPR-mediated knockdown/knockout of SLC52A2 should result in reduced or absent antibody signal

For in-depth validation, researchers can use purified recombinant RFVT2 protein as a reference standard. The recombinant protein can be expressed in E. coli, purified using affinity chromatography, and identified using both anti-SLC52A2 antibodies and anti-His tag antibodies if a His-tag system is used .

What methodological approaches are recommended for using SLC52A2 antibodies in cancer research?

Given the significant upregulation of SLC52A2 in multiple cancer types, several methodological approaches can maximize the utility of SLC52A2 antibodies in cancer research:

• Tissue Microarray (TMA) Analysis:

  • Create TMAs containing multiple tumor types alongside matched normal tissues

  • Use optimized immunohistochemistry protocols with SLC52A2 antibodies

  • Score expression levels using established quantification methods

  • Correlate expression with clinical parameters and survival data

• Multi-parameter Analysis:

  • Combine SLC52A2 antibodies with markers for cell proliferation, apoptosis, or cancer stem cells

  • Use multiplex immunofluorescence to assess co-expression patterns

  • Integrate findings with genomic and transcriptomic data

• Patient-derived Xenograft (PDX) Models:

  • Evaluate SLC52A2 expression in PDX models using immunohistochemistry

  • Monitor expression changes during tumor progression and in response to therapies

  • Correlate with riboflavin transport activity using functional assays

• Liquid Biopsy Applications:

  • Investigate SLC52A2 expression in circulating tumor cells using immunocytochemistry

  • Develop immunoassays to detect soluble forms of SLC52A2 in patient serum/plasma

How do experimental conditions affect SLC52A2 antibody performance in immunohistochemistry?

Optimizing experimental conditions is essential for achieving reliable and reproducible results with SLC52A2 antibodies in immunohistochemistry:

• Fixation and Tissue Processing:

  • Formalin fixation time significantly impacts epitope accessibility

  • Excessive fixation (>24 hours) may mask SLC52A2 epitopes

  • Optimal fixation: 10% neutral buffered formalin for 12-24 hours

  • Consider testing both FFPE and frozen sections for epitope preservation

• Antigen Retrieval Methods:

  • Heat-induced epitope retrieval (HIER) is typically effective

  • Compare citrate buffer (pH 6.0) versus EDTA buffer (pH 9.0)

  • Optimize retrieval time: 10-30 minutes at 95-100°C

  • For membrane proteins like SLC52A2, detergent-based permeabilization may improve accessibility

• Antibody Dilution and Incubation:

  • Determine optimal antibody concentration through titration experiments

  • Extended incubation (overnight at 4°C) may improve signal-to-noise ratio

  • Include controls for each experimental batch

• Detection Systems:

  • Polymer-based detection systems often provide better sensitivity than ABC methods

  • For dual immunofluorescence, ensure secondary antibodies have minimal cross-reactivity

  • Tyramide signal amplification can enhance detection of low-abundance targets

• Counterstaining and Visualization:

  • Optimize nuclear counterstaining to provide context without obscuring membrane staining

  • Consider image analysis software for quantitative assessment

How can SLC52A2 antibodies be used to investigate the relationship between riboflavin transport and cancer metabolism?

The emerging link between SLC52A2 overexpression and cancer provides an opportunity to investigate the role of riboflavin transport in cancer metabolism. SLC52A2 antibodies can be instrumental in this research through several sophisticated approaches:

• Metabolic Flux Analysis:

  • Use SLC52A2 antibodies to isolate high and low expressing populations from tumors

  • Combine with isotope-labeled riboflavin to track metabolic incorporation

  • Measure differential metabolic activities in FAD/FMN-dependent pathways

  • Correlate SLC52A2 expression levels with oxidative phosphorylation efficiency

• Proximity Ligation Assays (PLA):

  • Investigate protein-protein interactions between SLC52A2 and metabolic enzymes

  • Use SLC52A2 antibodies in combination with antibodies against FAD/FMN-dependent enzymes

  • Quantify interaction signals in different metabolic states or cancer progression stages

• Chromatin Immunoprecipitation (ChIP) Studies:

  • Investigate transcription factors regulating SLC52A2 expression in cancer

  • Correlate with metabolic reprogramming signatures

  • Identify potential therapeutic targets in the regulatory network

• Single-cell Analysis:

  • Combine SLC52A2 antibodies with metabolic markers for single-cell analysis

  • Identify metabolically distinct subpopulations within tumors

  • Correlate with stemness markers and therapeutic resistance

The regulatory relationship between SLC52A2 and cancer metabolism appears complex. Enrichment analysis has shown that SLC52A2 is mainly involved in oocyte meiosis, eukaryotic ribosome biogenesis, and cell cycle regulation . In hepatocellular carcinoma, regulatory pathways including the SNHG3 and THUMPD3-AS1/hsa-miR-139-5p-SLC52A2 axis have been identified . These findings suggest that SLC52A2 may influence cancer metabolism through both direct riboflavin transport effects and indirect regulatory mechanisms.

What techniques can discriminate between wild-type and mutant SLC52A2 variants associated with Brown-Vialetto-Van Laere syndrome?

Brown-Vialetto-Van Laere syndrome (BVVLS) is a rare neurological disorder associated with mutations in the SLC52A2 gene. Developing techniques to distinguish between wild-type and mutant SLC52A2 variants is critical for both research and diagnostic applications:

• Epitope-specific Antibodies:

  • Generate antibodies targeting common BVVLS mutation sites

  • Develop antibodies that selectively recognize wild-type but not mutant epitopes

  • Use paired antibodies (mutation-specific and pan-SLC52A2) for comparative analysis

• Functional Transport Assays:

  • Combine SLC52A2 antibodies with [³H]riboflavin uptake measurements in reconstituted systems

  • Compare transport kinetics between wild-type and mutant variants

  • Correlate antibody binding patterns with functional deficits

• Structural Analysis:

  • Use the homology model of RFVT2 with 11 α-helices crossing the membrane and 2 large hydrophilic loops

  • Determine how mutations affect protein conformation and antibody binding

  • Focus on the negatively charged cluster in one of the hydrophilic loops, which may be crucial for function

• Mass Spectrometry-based Approaches:

  • Develop SLC52A2 immunoprecipitation protocols optimized for membrane proteins

  • Use targeted mass spectrometry to identify mutation-specific peptides

  • Quantify wild-type to mutant ratios in heterozygous samples

For expression studies, researchers can leverage the recombinant protein expression system described in the literature, where human RFVT2 has been overexpressed in E. coli, purified and reconstituted into proteoliposomes . This system allows for direct comparison of wild-type and mutant protein behavior in a controlled environment.

How can SLC52A2 antibodies be integrated into multi-parameter imaging systems for investigating tumor heterogeneity?

Tumor heterogeneity presents a significant challenge in cancer research and treatment. Advanced integration of SLC52A2 antibodies into multi-parameter imaging systems can provide valuable insights:

• Multiplex Immunofluorescence Panels:

  • Design panels including SLC52A2 alongside markers for:

    • Cancer stem cells (CD44, ALDH1)

    • Proliferation (Ki-67, PCNA)

    • Hypoxia (HIF-1α, CA IX)

    • Immune cell infiltration (CD8, CD68, FoxP3)

  • Use spectral unmixing to resolve overlapping fluorophores

  • Apply automated image analysis algorithms for quantitative assessment

• Mass Cytometry Imaging (IMC):

  • Label anti-SLC52A2 antibodies with rare earth metals

  • Combine with up to 40 additional markers in a single tissue section

  • Generate high-dimensional datasets for advanced computational analysis

  • Create spatial maps of SLC52A2 expression in relation to tumor microenvironment

• Digital Spatial Profiling:

  • Use antibody-based spatial profiling with SLC52A2 antibodies

  • Correlate with RNA expression patterns in the same tissue regions

  • Identify spatial relationships between SLC52A2 expression and metabolic zones

• 3D Tissue Imaging:

  • Apply tissue clearing techniques compatible with antibody penetration

  • Use confocal or light-sheet microscopy for 3D visualization

  • Map SLC52A2 expression throughout the tumor volume

Research has shown that SLC52A2 expression is associated with immune checkpoint genes and immune cell infiltration . A comprehensive imaging approach can help elucidate these relationships by simultaneously visualizing SLC52A2 expression and immune cell distribution within the tumor microenvironment.

Given the association of SLC52A2 with tumor mutational burden and microsatellite instability , integrating genomic information with spatial antibody-based imaging can provide more comprehensive insights into tumor biology and potential therapeutic strategies.

What are the optimal procedures for extracting membrane-bound SLC52A2 for western blot analysis?

Membrane proteins like SLC52A2 present unique challenges for extraction and analysis. The following optimized protocol can improve detection in western blot applications:

• Enhanced Membrane Protein Extraction:

  • Use specialized membrane protein extraction buffers containing:

    • Non-denaturing detergents (0.1% C₁₂E₈ has been effective for SLC52A2)

    • Protease inhibitor cocktail (must include membrane protease inhibitors)

    • Phosphatase inhibitors if phosphorylation status is important

  • Perform extraction at 4°C with gentle agitation for 30-60 minutes

  • Consider sequential extraction with increasing detergent concentrations

• Sample Preparation for SDS-PAGE:

  • Avoid boiling samples (heat to 37°C for 30 minutes instead)

  • Include reducing agents (DTT or β-mercaptoethanol) to disrupt disulfide bonds

  • Use 6M urea in sample buffer for improved denaturation

  • Load higher protein amounts (50-100 μg) than typically used for cytosolic proteins

• Gel Electrophoresis Considerations:

  • Use gradient gels (4-15%) for better resolution

  • Consider specialized gel systems designed for membrane proteins

  • Run at lower voltage (80-100V) to prevent overheating

• Transfer Optimization:

  • Use PVDF membranes (0.45 μm pore size) for better protein retention

  • Add 0.05% SDS to transfer buffer to aid in the migration of hydrophobic proteins

  • Transfer at low current overnight at 4°C for complete transfer

  • Consider semi-dry transfer systems with specialized buffers for membrane proteins

When analyzing the results, researchers should be aware that membrane proteins can sometimes appear at unexpected molecular weights due to incomplete denaturation or post-translational modifications. The expected molecular weight of SLC52A2 is approximately 45.8 kDa , but validation with recombinant protein controls is recommended.

What strategies can improve immunoprecipitation of SLC52A2 for protein interaction studies?

Immunoprecipitation (IP) of membrane proteins like SLC52A2 requires special considerations to maintain protein interactions while effectively solubilizing the target:

• Optimized Cell Lysis and Solubilization:

  • Test multiple detergents for optimal solubilization while preserving interactions:

    • Digitonin (0.5-1%): Mild, preserves many protein complexes

    • CHAPS (0.5-1%): Zwitterionic detergent good for membrane proteins

    • DDM (0.5%): Effective for many membrane protein complexes

    • C₁₂E₈ (0.1%): Shown to be effective for SLC52A2 purification

  • Include physiologically relevant salt concentrations (150-200 mM NaCl)

  • Buffer with 10 mM Tris-HCl pH 8.0 appears suitable for SLC52A2

• Antibody Coupling Strategies:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Consider covalently coupling antibodies to beads to prevent antibody contamination in eluted samples

  • For weak interactions, use crosslinking agents (DSP, formaldehyde) before lysis

• Co-IP Protocol Modifications:

  • Extend incubation times (overnight at 4°C) to improve capture efficiency

  • Use gentle washing conditions to preserve weak interactions

  • Consider on-bead digestion for subsequent mass spectrometry analysis

  • For elution, use competitive peptides rather than harsh denaturing conditions

• Verification Approaches:

  • Perform reverse IP with antibodies against suspected interaction partners

  • Include multiple controls (IgG control, lysate control, knockdown control)

  • Confirm interactions with orthogonal methods (proximity ligation assay, FRET)

For SLC52A2 specifically, potential interaction partners may include metabolic enzymes requiring FAD/FMN as cofactors or other membrane transporters. The identification of regulatory pathways such as the SNHG3 and THUMPD3-AS1/hsa-miR-139-5p-SLC52A2 axis in hepatocellular carcinoma suggests that SLC52A2 may be involved in complex regulatory networks that could be investigated through carefully optimized IP experiments .

How can SLC52A2 antibodies contribute to developing targeted therapies for cancers with high SLC52A2 expression?

The overexpression of SLC52A2 in numerous cancer types presents potential opportunities for targeted therapeutic approaches. SLC52A2 antibodies can facilitate these developments through several research avenues:

• Therapeutic Antibody Development:

  • Screen antibodies for those that block riboflavin transport function

  • Evaluate antibody-drug conjugates (ADCs) targeting SLC52A2-overexpressing cells

  • Assess internalization kinetics of anti-SLC52A2 antibodies for effective ADC delivery

  • Develop bispecific antibodies linking SLC52A2-expressing cells to immune effectors

• Patient Stratification Biomarkers:

  • Establish standardized IHC protocols for SLC52A2 detection in clinical samples

  • Develop quantitative scoring systems correlating with therapeutic response

  • Create companion diagnostic assays for trials targeting riboflavin metabolism

  • Integrate with other biomarkers associated with SLC52A2 expression

• Combination Therapy Approaches:

  • Investigate synergies between riboflavin transport inhibition and:

    • Metabolic pathway inhibitors

    • DNA damage response modulators

    • Immune checkpoint inhibitors

  • Use SLC52A2 antibodies to monitor target engagement in preclinical models

• Functional Screening Platforms:

  • Develop cell-based assays with SLC52A2 antibodies for high-throughput screening

  • Create reporter systems for SLC52A2 expression and activity

  • Identify compounds that selectively target cells with high SLC52A2 expression

What is the potential role of SLC52A2 in neurodegenerative disorders beyond Brown-Vialetto-Van Laere syndrome?

While SLC52A2 mutations are well-established in Brown-Vialetto-Van Laere syndrome (BVVLS), emerging evidence suggests potential implications in other neurodegenerative conditions. SLC52A2 antibodies can facilitate investigation of these broader neurological connections:

• Comparative Expression Studies:

  • Map SLC52A2 expression patterns across neurodegenerative disease tissues

  • Compare with age-matched controls using standardized IHC protocols

  • Examine subcellular localization changes in disease states

  • Assess co-localization with disease-specific protein aggregates

• Animal Model Investigations:

  • Analyze SLC52A2 expression in models of Alzheimer's, Parkinson's, and ALS

  • Develop conditional knockdown models to assess neurodegeneration mechanisms

  • Test riboflavin supplementation effects on disease progression

  • Monitor metabolic changes in FAD/FMN-dependent pathways

• Mechanistic Studies:

  • Investigate oxidative stress pathways in relation to SLC52A2 dysfunction

  • Assess mitochondrial function in cells with altered SLC52A2 expression

  • Examine potential links between riboflavin transport and protein misfolding

• Clinical Correlation Studies:

  • Develop sensitive ELISAs for SLC52A2 in cerebrospinal fluid

  • Correlate levels with disease progression markers

  • Sequence SLC52A2 in neurodegenerative disease cohorts

  • Test for SLC52A2 autoantibodies in neurological conditions

Research has identified riboflavin deficiency as a risk factor for neurodegeneration . Since SLC52A2 is highly expressed in the brain and fetal brain , and mediates essential riboflavin transport, alterations in its expression or function could contribute to neurological dysfunction through impaired energy metabolism, increased oxidative stress, or disrupted neuronal maintenance pathways.

The investigation of SLC52A2 in broader neurodegenerative contexts may reveal new therapeutic approaches focusing on riboflavin transport and metabolism, potentially applicable across multiple neurological conditions.

How can researchers integrate SLC52A2 antibody data with multi-omics datasets for comprehensive pathway analysis?

Modern research increasingly requires integration of protein expression data with other -omics layers. SLC52A2 antibody-derived data can be effectively integrated into multi-omics analyses through:

• Integrated Workflow Design:

  • Collect matched samples for:

    • Protein expression (antibody-based)

    • Transcriptomics (RNA-seq)

    • Metabolomics (focus on FAD/FMN-dependent pathways)

    • Epigenomics (regulatory mechanisms)

  • Establish standardized processing and normalization procedures

  • Develop quality control metrics specific to membrane proteins

• Computational Integration Methods:

  • Apply multi-omics factor analysis (MOFA) to identify latent factors

  • Use similarity network fusion (SNF) to combine different data types

  • Implement Bayesian network approaches for causal relationship inference

  • Develop integrated visualization techniques for complex datasets

• Pathway-focused Analysis:

  • Target known riboflavin-dependent metabolic pathways

  • Investigate the SNHG3 and THUMPD3-AS1/hsa-miR-139-5p-SLC52A2 regulatory axis

  • Connect to enriched pathways (oocyte meiosis, eukaryotic ribosome biogenesis, cell cycle)

  • Map to immune infiltration and checkpoint regulation networks

• Clinical Data Integration:

  • Correlate integrated molecular profiles with:

    • Patient survival metrics (OS, DSS, PFI)

    • Treatment response patterns

    • Clinical features (stage, grade)

  • Develop predictive models incorporating SLC52A2 expression data

Published research has already begun this integration process, revealing that SLC52A2 expression correlates with tumor mutational burden, microsatellite instability, immune checkpoint genes, and immune cell infiltration . Further integration could reveal mechanistic connections between these observations and identify key nodes for therapeutic intervention.

The data table below illustrates potential connections between SLC52A2 expression and various cancer characteristics based on integrated analysis: